Chronic pain

Dr. Trey Mouch Joins Central Texas Pain Center in Austin and Bee Cave

Thursday, July 29, 2021 - 12:00pm

AUSTIN, Texas, July 29, 2021 /PRNewswire/ --Central Texas Pain Center is pleased to announce that Dr. Trey Mouch has joined the Central Texas Pain Center team after finishing his interventional pain fellowship at Weill Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Hospital for Special Surgery in New York.Dr.

Key Points: 
  • AUSTIN, Texas, July 29, 2021 /PRNewswire/ --Central Texas Pain Center is pleased to announce that Dr. Trey Mouch has joined the Central Texas Pain Center team after finishing his interventional pain fellowship at Weill Cornell Medical Center, Memorial Sloan-Kettering Cancer Center and Hospital for Special Surgery in New York.Dr.
  • Mouch will be providing patient care for Central Texas Pain Center in the rapidly growing Central and South Austin and Bee Cave neighborhoods of Austin, TX.
  • A native of Dallas, Texas, Dr. Mouch completed medical school at the University of Texas Health Science Center San Antonio.He has special interests in cancer pain, peripheral nerve therapies, and minimally invasive spinal therapy, including spinal cord stimulation and spinal decompression Therapies.
  • In addition, he firmly believes in a personalized and multidisciplinary approach to pain management to reduce patients' level of pain and increase their quality of life.

NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

Monday, July 26, 2021 - 2:00pm

WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research.

Key Points: 
  • WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research.
  • Note: The use of Quell for fibromyalgia is investigational and has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
  • Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep, cognitive and mood disturbances.
  • Quell is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain.

XRHealth and Reducept Offer Patients Virtual Reality Therapy for Pain Management

Monday, July 26, 2021 - 12:00pm

BOSTON, July 26, 2021 /PRNewswire/ -- XRHealth ,the leader in extended reality and therapeutic applications,announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management.

Key Points: 
  • BOSTON, July 26, 2021 /PRNewswire/ -- XRHealth ,the leader in extended reality and therapeutic applications,announced today that they are working with Reducept to expand their offering to patients for virtual reality therapy for pain management.
  • The virtual reality technology provides exercises that train people suffering from chronic pain on how to gain control over pain, potentially reducing the need for medication.
  • The Reducept VR Game trains the users' brain to create its own pain medication via digital psychological pain treatment.
  • XRHealth operates state-of-the-art therapeutic care Virtual Clinics, utilizing proprietary FDA and CE registered medical Extended Reality (XR) technology (virtual and augmented reality).

The Gulf Pain Management Drugs Industry is Expected to Reach $1+ Billion by 2027 - ResearchAndMarkets.com

Friday, July 23, 2021 - 4:05pm

The "Gulf Pain Management Drugs Market by Drug Class, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gulf Pain Management Drugs Market by Drug Class, Indication, Pain Type: Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Gulf Pain Management Drugs Market was valued at $851.08 million in 2019, and is projected to reach $1,047.91 million by 2027, registering a CAGR of 3.2%.
  • The length of the pain would range from acute pain for short term to chronic pain for long term.
  • The Gulf pain management drugs market is segmented on the basis of drug class, indication, pain type, and region.

The Cake House Using Clinical Prescription Cannabis To Help Veterans Combat PTSD, Chronic Pain

Thursday, July 22, 2021 - 4:56pm

A recent study of 60,000 Iraq and Afghanistan veterans said 13.5 percent of deployed and non-deployed veterans screened positive for PTSD.

Key Points: 
  • A recent study of 60,000 Iraq and Afghanistan veterans said 13.5 percent of deployed and non-deployed veterans screened positive for PTSD.
  • That is why The Cake House is supplying the veteran community with trusted medicine to combat the effects of PTSD, reduce chronic pain, nausea and many other common ailments veterans and civilians face.
  • Thats why The Cake House works diligently every day to provide veterans alternative solutions to combat different types of chronic ailments.
  • The Cake House is playing a major role in reducing these numbers by supplying safe, clinical prescription, over-the-counter cannabis and hemp-based medications to reduce pain, addiction and deaths.

BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021

Thursday, July 22, 2021 - 1:00pm

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.

Key Points: 
  • BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.
  • BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
  • BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
  • 2021BioDelivery Sciences International, Inc. All rights reserved.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Wednesday, July 21, 2021 - 1:45pm

Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Wednesday, July 21, 2021 - 1:45pm

NEW YORK, July 21, 2021 /PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4%  and 20.6% of the adult population respectively. As psychedelics gain more recognition, companies such as Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Seelos Therapeutics (NASDAQ:SEEL), Numinus Wellness Inc. (TSXV:NUMI) (OTC:LKYSF), Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED), and Mydecine Innovations Group Inc. (NEO:MYCO) (OTCPK:MYCOF) are engaging in research initiatives to develop psychedelic-assisted therapies for different mental illnesses and chronic pain conditions.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Canada’s surgery backlog could lead to wave of new chronic pain and opioid dependencies

Wednesday, July 21, 2021 - 11:00am

TORONTO, July 21, 2021 (GLOBE NEWSWIRE) -- As Canada’s vaccination rates climb and hospitals begin to tackle the mountain of postponed surgeries due to the pandemic, we are facing an echo epidemic of new chronic pain sufferers. Studies show that roughly 30 per cent of those undergoing surgery will go on to develop chronic pain, and about 25 per cent of all chronic pain conditions originate from surgical procedures.1,2 This has a detrimental effect on families, communities and the healthcare system. However, with recent innovations in genetic testing this does not have to be the fate for the thousands of Canadians who are about to have surgery.

Key Points: 
  • Studies show that roughly 30 per cent of those undergoing surgery will go on to develop chronic pain, and about 25 per cent of all chronic pain conditions originate from surgical procedures.1,2 This has a detrimental effect on families, communities and the healthcare system.
  • However, with recent innovations in genetic testing this does not have to be the fate for the thousands of Canadians who are about to have surgery.
  • The risk of chronic pain following surgery is high.
  • The risk may be further compounded by the current echo pandemic of mental health issues, as depression and anxiety significantly increase the risk of developing chronic pain after surgery.

Multi-Center Study of SPRINT® PNS System for Chronic Low Back Pain Demonstrates Clinically Significant Improvements in Pain and Quality of Life

Monday, July 12, 2021 - 1:00pm

73 percent of participants experienced a clinically significant reduction in average pain intensity with an average reduction in pain intensity of 58 percent among this group.

Key Points: 
  • 73 percent of participants experienced a clinically significant reduction in average pain intensity with an average reduction in pain intensity of 58 percent among this group.
  • Participants also reported substantial and statistically significant improvements in secondary endpoints including changes in health-related Quality of Life (QoL), patient global impression of change, and depression.
  • The system has been studied extensively for low back pain, shoulder pain, post-amputation pain, and chronic and acute post-operative pain, and iscleared for use up to 60 days.
  • Our SPRINT PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain.